Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
NCT ID: NCT00334815
Last Updated: 2025-08-24
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
PHASE2
29 participants
INTERVENTIONAL
2006-06-15
2026-02-22
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
S9712: Radiation Therapy and Combination Chemotherapy in Treating Patients With Stage III Non-small Cell Lung Cancer
NCT00003158
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery
NCT00324805
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Can Not Be Surgically Removed
NCT00003235
Carboplatin, Paclitaxel, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed During Surgery
NCT00003387
Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer
NCT00280150
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. Determine the frequency and severity of toxic effects of induction therapy comprising cisplatin, etoposide, and radiotherapy with or without bevacizumab followed by consolidation therapy comprising docetaxel and bevacizumab, in terms of grade 4 or 5 hemorrhage, in patients with newly diagnosed, unresectable, stage III non-small cell lung cancer.
SECONDARY OBJECTIVES:
I. Determine progression-free and overall survival of patients treated with these regimens.
II. Determine response (confirmed, unconfirmed, partial, and complete) in patients with measurable disease treated with these regimens.
OUTLINE: This is a pilot, multicenter study. Patients are stratified according to risk (high\* vs low).
NOTE: \*High-risk stratum closed to accrual as of 2/20/09.
INDUCTION THERAPY: Patients in each stratum are assigned to 1 of 3 sequential treatment groups.
GROUP 1: Patients receive cisplatin intravenously (IV) over 1 hour on days 1, 8, 29, and 36 and etoposide IV over 1 hour on days 1-5 and 29-33. Patients undergo concurrent thoracic radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, 36-40, and 43-47.
GROUP 2: Patients receive cisplatin, etoposide, and thoracic radiotherapy as in group 1. Patients also receive bevacizumab IV over 30-90 minutes on days 15, 36, and 57.
GROUP 3: Patients receive cisplatin, etoposide, and thoracic radiotherapy as in group 1. Patients also receive bevacizumab IV over 30-90 minutes on days 1, 22, and 43.
CONSOLIDATION CHEMOTHERAPY: Beginning 3-6 weeks after completion of induction therapy, all patients receive consolidation chemotherapy comprising docetaxel IV over 1 hour and bevacizumab IV over 30-90 minutes on day 1. Patients also receive filgrastim (G-CSF) subcutaneously (SC) beginning on day 2 and continuing until blood counts recover OR pegfilgrastim SC once on day 2.
Treatment repeats every 21 days for 3 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, patients are followed periodically for up to 4 years.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1 (cisplatin, etoposide, radiotherapy)
Patients receive cisplatin IV over 1 hour on days 1, 8, 29, and 36 and etoposide IV over 1 hour on days 1-5 and 29-33. Patients undergo concurrent thoracic radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, 36-40, and 43-47.
Cisplatin
Given IV
Docetaxel
Given IV
Etoposide
Given IV
Filgrastim
Given SC
Pegfilgrastim
Given SC
Radiation Therapy
Undergo thoracic radiotherapy
Group 2 (cisplatin, etoposide, radiotherapy, bevacizumab)
Patients receive cisplatin, etoposide, and thoracic radiotherapy as in group 1. Patients also receive bevacizumab IV over 30-90 minutes on days 15, 36, and 57.
Bevacizumab
Given IV
Cisplatin
Given IV
Docetaxel
Given IV
Etoposide
Given IV
Filgrastim
Given SC
Pegfilgrastim
Given SC
Radiation Therapy
Undergo thoracic radiotherapy
Group 3 (cisplatin, etoposide, radiotherapy, bevacizumab)
Patients receive cisplatin, etoposide, and thoracic radiotherapy as in group 1. Patients also receive bevacizumab IV over 30-90 minutes on days 1, 22, and 43.
Bevacizumab
Given IV
Cisplatin
Given IV
Docetaxel
Given IV
Etoposide
Given IV
Filgrastim
Given SC
Pegfilgrastim
Given SC
Radiation Therapy
Undergo thoracic radiotherapy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bevacizumab
Given IV
Cisplatin
Given IV
Docetaxel
Given IV
Etoposide
Given IV
Filgrastim
Given SC
Pegfilgrastim
Given SC
Radiation Therapy
Undergo thoracic radiotherapy
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Newly diagnosed disease
* Unresectable disease
* No more than 1 parenchymal lesions on same or opposite sides of the lungs
* Meets 1 of the following stage criteria:
* Stage IIIA (N2) disease meeting the following criteria:
* N2 mediastinal lymph nodes must be multiple and/or bulky on CT scan or x-ray so that the patient is not a candidate for induction chemotherapy or chemoradiotherapy followed by surgical resection
* N2 status must be documented by ≥ 1 of the following methods:
* Histologically or cytologically confirmed N2 disease by exploratory thoracotomy, thoracoscopy, mediastinoscopy, mediastinotomy, Chamberlain procedure, Wang needle biopsy (WNB), fine needle aspiration (FNA) under bronchoscopic or CT guidance, or any other method
* Node positive by fludeoxyglucose-positron emission tomography (FDG-PET) scan
* Nodes \> 3 cm on CT scan
* Paralyzed left true vocal cord with separate left lung primary distinct from anterior-posterior window nodes on CT scan
* Stage IIIB disease meeting ≥ 1 of the following criteria:
* Histologically or radiographically confirmed positive N3 nodes\*, documented by ≥ 1 of the following methods:
* FNA, core needle biopsy (CNB), or excisional biopsy of supraclavicular N3 nodes
* Biopsy of contralateral mediastinal N3 nodes by mediastinoscopy, mediastinotomy, or thoracotomy
* FNA, CNB, or WNB under CT or bronchoscopic fluoroscopic guidance of enlarged contralateral N3 mediastinal nodes
* Contralateral mediastinal nodes \> 3 cm on CT scan
* Node positivity by FDG-PET scan
* Right-sided primary with paralyzed left true vocal cord
* T4 lesions of any size that invade the mediastinum, heart, great vessels, trachea, esophagus, vertebral body, or carina, documented by ≥ 1 of the following methods:
* Written documentation of type of T4 extent if patient had a prior exploratory thoracotomy or thoracoscopy
* T4 involvement of the trachea or carina by direct bronchoscopic visualization
* T4 involvement of the heart, esophagus, aorta, or vertebral body by CT scan, MRI, or transesophageal ultrasound
* T4 involvement of the mediastinum by CT scan or MRI if, in the absence of the above organ involvement, there is soft tissue extension directly into the mediastinal space\*\*
* Meets 1 of the following risk criteria:
* Low risk disease, meeting the following criteria:
* Non-squamous cell NSCLC, including adenocarcinoma, bronchoalveolar cell carcinoma, or large cell carcinoma
* If mixed histology, the squamous cell carcinoma component must be \< 50%
* Histology or cytology from involved mediastinal or supraclavicular lymph nodes allowed if a separate distal primary lesion is clearly evident on radiographs (i.e., second biopsy not required)
* No primary tumor with cavitation and/or tumor within 1 cm of a major vessel
* No hemoptysis (i.e., bright red blood ≥ ½ teaspoon) in the past 28 days
* High-risk\* disease, meeting ≥ 1 of the following criteria:
* Squamous cell NSCLC
* If mixed histology, the squamous cell component must be ≥ 50%
* Tumor with any histology that has cavitation or is located within 1 cm of a major vessel
* No aortic involvement
* Any histology and hemoptysis (i.e., bright red blood ≥ ½ teaspoon) within past 28 days
* Measurable or nonmeasurable disease by CT scan or MRI
* Pleural effusions, ascites, and laboratory parameters are not acceptable as the only evidence of disease
* No pleural effusion except for small pleural effusion visible on CT scan or MRI alone
* No pericardial effusions
* No metastatic disease involving the contralateral chest, liver, or adrenals confirmed by CT scan of the upper abdomen or by chest CT scan with complete liver and adrenals in the report
* Patients must be offered participation in SWOG-S9925 (Lung Cancer Specimen Repository Protocol)
* No brain metastases by CT scan or MRI
* No evidence of cavitation
* Creatinine normal
* Creatinine clearance ≥ 50 mL/min
* FEV\_1 ≥ 2.0 liters OR predicted FEV\_1 of the contralateral lung \> 800 mL
* Absolute neutrophil count ≥ 1,500/mm\^3
* Platelet count ≥ 100,000/mm\^3
* Urine protein: creatinine ratio ≤ 0.5 by urinalysis OR urine protein \< 1,000 mg by 24-hour urine collection
* INR \< 1.5
* Zubrod performance status 0-1
* No sensory neuropathy \> grade 1
* No cerebrovascular accident within the past 6 months
* No myocardial infarction or unstable angina within the past 6 months
* No uncontrolled hypertension
* No New York Heart Association class II-IV congestive heart failure
* No serious cardiac arrhythmia requiring medication
* No clinically significant peripheral vascular disease
* No evidence of bleeding diathesis or coagulopathy
* No pathologic condition other than lung cancer that carries a high risk of bleeding
* No known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies
* No serious, nonhealing wound, ulcer, or bone fracture
* No other prior malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer for which the patient is currently in complete remission, or other cancer for which the patient has been disease-free for 5 years
* Not pregnant or nursing
* No nursing during and for ≥ 6 months after the last dose of bevacizumab
* Negative pregnancy test
* Fertile patients must use effective contraception during and for ≥ 6 months after the last dose of bevacizumab
* Must have pre-treatment simulation demonstrating a V20 ≤ 35% with planned radiation dose of 6,480 cGy
* No prior surgical resection
* Prior exploratory thoracotomy, mediastinoscopy, excisional biopsy, or similar surgery allowed for diagnosing, staging, or determining potential resectability of lung tumor
* No prior chemotherapy or radiotherapy for lung cancer
* No prior radiotherapy to the neck or thorax
* At least 4 weeks since prior thoracic or other major surgery (excluding mediastinoscopy) and recovered
* More than 7 days since prior FNA, CNB, or mediastinoscopy
* No other concurrent anticancer therapy, including chemotherapy, radiotherapy, or biologic agents
* No other concurrent investigational drugs
* No concurrent major surgical procedures
* No concurrent full-dose anticoagulants (e.g., low-molecular weight and unfractionated heparin or warfarin)
* Low-dose warfarin (i.e., 1 mg) is allowed to prevent clotting of an infusaport or central line
* No concurrent brachytherapy, radiopharmaceuticals, high linear energy transfer radiation (i.e., fast neutrons), particle therapy (i.e., protons, carbon, or helium), and/or altered fractionation schemes
* No concurrent intensity-modulated radiotherapy
* No concurrent prophylactic contralateral hilar or supraclavicular lymph node radiotherapy
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Antoinette J Wozniak
Role: PRINCIPAL_INVESTIGATOR
SWOG Cancer Research Network
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Providence Hospital
Mobile, Alabama, United States
Saint Bernards Regional Medical Center
Jonesboro, Arkansas, United States
University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States
Highlands Oncology Group - Rogers
Rogers, Arkansas, United States
USC / Norris Comprehensive Cancer Center
Los Angeles, California, United States
Fremont - Rideout Cancer Center
Marysville, California, United States
UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California, United States
University of California Davis Comprehensive Cancer Center
Sacramento, California, United States
Providence Santa Rosa Memorial Hospital
Santa Rosa, California, United States
Gene Upshaw Memorial Tahoe Forest Cancer Center
Truckee, California, United States
Northbay Cancer Center
Vacaville, California, United States
Rocky Mountain Regional VA Medical Center
Aurora, Colorado, United States
UCHealth University of Colorado Hospital
Aurora, Colorado, United States
Denver Health Medical Center
Denver, Colorado, United States
University of Colorado
Denver, Colorado, United States
Shaw Cancer Center
Edwards, Colorado, United States
Valley View Hospital Cancer Center
Glenwood Springs, Colorado, United States
Montrose Memorial Hospital
Montrose, Colorado, United States
Cancer Centers of Central Florida PA
Leesburg, Florida, United States
Lewis Cancer and Research Pavilion at Saint Joseph's/Candler
Savannah, Georgia, United States
Loyola University Medical Center
Maywood, Illinois, United States
Edward Hospital/Cancer Center
Naperville, Illinois, United States
HaysMed
Hays, Kansas, United States
Hutchinson Regional Medical Center
Hutchinson, Kansas, United States
University of Kansas Cancer Center
Kansas City, Kansas, United States
Olathe Cancer Center
Olathe, Kansas, United States
Salina Regional Health Center
Salina, Kansas, United States
University of Kansas Health System Saint Francis Campus
Topeka, Kansas, United States
LSU Health Sciences Center at Shreveport
Shreveport, Louisiana, United States
Highland Clinic
Shreveport, Louisiana, United States
Dana-Farber Cancer Institute at Boston Medical Center - Brighton
Brighton, Massachusetts, United States
Wayne State University/Karmanos Cancer Institute
Detroit, Michigan, United States
McLaren Cancer Institute-Macomb
Mount Clemens, Michigan, United States
University of Mississippi Medical Center
Jackson, Mississippi, United States
Kansas City Veterans Affairs Medical Center
Kansas City, Missouri, United States
Montana Cancer Consortium NCORP
Billings, Montana, United States
Benefis Sletten Cancer Institute
Great Falls, Montana, United States
Arnot Ogden Medical Center/Falck Cancer Center
Elmira, New York, United States
Highland Hospital
Rochester, New York, United States
University of Rochester
Rochester, New York, United States
Novant Health Presbyterian Medical Center
Charlotte, North Carolina, United States
Southeast Clinical Oncology Research Consortium NCORP
Winston-Salem, North Carolina, United States
Oregon Health and Science University
Portland, Oregon, United States
Portland VA Medical Center
Portland, Oregon, United States
Roper Hospital
Charleston, South Carolina, United States
Wellmont Holston Valley Hospital and Medical Center
Kingsport, Tennessee, United States
University of Tennessee Health Science Center
Memphis, Tennessee, United States
The Don and Sybil Harrington Cancer Center
Amarillo, Texas, United States
M D Anderson Cancer Center
Houston, Texas, United States
Audie L Murphy VA Hospital
San Antonio, Texas, United States
Cancer Therapy and Research Center at The UT Health Science Center at San Antonio
San Antonio, Texas, United States
University Hospital
San Antonio, Texas, United States
University of Texas Health Science Center at San Antonio
San Antonio, Texas, United States
Danville Regional Medical Center
Danville, Virginia, United States
Ballad Health Cancer Care - Norton
Norton, Virginia, United States
MultiCare Auburn Medical Center
Auburn, Washington, United States
Providence Regional Cancer System-Centralia
Centralia, Washington, United States
Saint Francis Hospital
Federal Way, Washington, United States
Saint Clare Hospital
Lakewood, Washington, United States
Providence - Saint Peter Hospital
Olympia, Washington, United States
MultiCare Good Samaritan Hospital
Puyallup, Washington, United States
MultiCare Allenmore Hospital
Tacoma, Washington, United States
Saint Joseph Medical Center
Tacoma, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2009-01097
Identifier Type: REGISTRY
Identifier Source: secondary_id
SWOG-S0533
Identifier Type: -
Identifier Source: secondary_id
CDR0000472907
Identifier Type: -
Identifier Source: secondary_id
S0533
Identifier Type: OTHER
Identifier Source: secondary_id
S0533
Identifier Type: OTHER
Identifier Source: secondary_id
NCI-2009-01097
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.